Loading provider…
Loading provider…
Hematology & Oncology Physician in San Diego, CA
NPI: 1164480943Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D., PH.D. Gregory's Phone Numberphone_androidMobile
Get M.D., PH.D. Gregory's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2005 - 2025
MN State Medical License
2000 - 2006

American Board of Internal Medicine
Medical Oncology
Mayo Clinic Alix School of Medicine - Rochester
college.mayo.edu
Fellowship • Hematology and Medical Oncology
2002 - 2005
Residency • Internal Medicine
1999 - 2002
Keck School of Medicine of USC
keck.usc.edu
Medical School
Until 1999
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 198 | 541 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 40 | 40 |
| 3 | 99497Advance care planning by the physician or other qualified health care professional | 25 | 28 |
| 4 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 13 | 22 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 11 | 26 |
Authors: Catherine Devine, Maria Cabanillas, Naifa Busaidy
Journal: Thyroid
Publication Date: 2022-07-05
Authors: Toman, P D, Chisholm, G, McMullin, H, Giere, L M, Olsen, D R, Kovach, R J, Leigh, S D, Fong, B E, Chang, R, Daniels, G A, Berg, R A, Hitzeman, R A
Journal: J Biol Chem
Melanoma, version 4.2014: Featured updates to the NCCN guidelines
Authors: Nikhil Khushalani, Adil Daud, Kenneth Tanabe, Vijay Trisal, Merrick Ross, Allan Halpern, William Carson, Susan Swetter, Robert Andtbacka
Publication Date: 2014-05
Lead Sponsor: Replimune Inc.
Intervention / Treatment: BIOLOGICAL: RP1, intra-tumoral injection, oncolytic virus
Lead Sponsor: Replimune Inc.
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: BIOLOGICAL: RP1, BIOLOGICAL: nivolumab
Lead Sponsor: Neurogene Inc.
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: NL-201, DRUG: Pembrolizumab Injection [Keytruda]